Number of patients in each category of medications with details of resolution of enthesitis (N = 526).
| Medications in Each Category | n (%) | No. of Patients on Each Medication (%) | Average Time on Treatment, Years (SD) | Resolution of Enthesitis, n (%) | |
|---|---|---|---|---|---|
| Yes | No | ||||
| Category I | 142 (27.00) | 2.58 (3.69) | 117 (82.39) | 25 (17.61) | |
| No medication | 52 (36.66) | NA | |||
| NSAID | 90 (63.38) | 2.58 (3.69) | |||
| Category II | 196 (37.26) | 3.06 (4.58) | 173 (88.26) | 23 (11.73) | |
| Methotrexate | 150 (76.53)a | 2.93 (4.61) | |||
| Leflunomide | 29 (14.79) | 1.74 (2.82) | |||
| Sulfasalazine | 32 (16.32) | 2.69 (3.50) | |||
| Azathioprine | 10 (5.10) | 5.82 (7.00) | |||
| Cyclosporine | 2 (1.02) | 2.34 (0.33) | |||
| Category III | 188 (35.74) | 1.72 (2.23) | 163 (86.70) | 25 (13.30) | |
| Targeted bDMARDs | |||||
| TNFib | 155 (82.45) | 1.86 (2.39) | |||
| IL-17ic | 14 (7.44) | 1.18 (1.09) | |||
| IL-12/23i, IL-23i | 18 (9.57) | 0.94 (0.97) | |||
| Targeted sDMARDs | |||||
| PDE-5i (Apremilast) | 1 (0.50) | – | |||
| JAKi (Tofacitinib) | 0 (0) | – | |||
| Total patients with and without resolution of enthesitis | 453 (86.12) | 73 (13.88) | |||
| Male | 240 (52.98) | 41 (56.16) | |||
| Females | 213 (47.02) | 32 (43.83) | |||
↵aPercentage of individual medications do not add to 100 as some patients were on combination cDMARDs.
↵bIncludes etanercept, adalimumab, infliximab, golimumab, and certolizumab pegol.
↵cIncludes secukinumab and ixekizumab. bDMARD: biologic disease-modifying antirheumatic drug; IL-17i: interleukin 17 inhibitor; IL-12/23i: interleukin 12/23 inhibitor; JAKi: Janus kinase inhibitor; NA: not applicable; NSAID: nonsteroidal antiinflammatory drug; PDE-5i: phosphodiesterase-5 inhibitor; sDMARD: synthetic disease-modifying antirheumatic drug; TNFi: tumor necrosis factor inhibitor.